摘要
目的探讨1／3剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变（CSC）的疗效。方法选择2013年2月至2014年10月经眼底检查、光学相干断层扫描（OCT）检查、眼底荧光血管造影（FFA）及吲哚菁绿造影（ICGA）检查并结合患者的病史诊断为慢性CSC患者23例23只眼，采用1／3剂量维替泊芬及经专用激光裂隙灯行光动力疗法（PDT）治疗。维替泊芬注入8min后，在吲哚菁绿的引导下激光照射30s。术后随访6～10个月，平均7-3个月；随访期间进行最佳矫正视力（BCVA）、眼底荧光血管造影（FFA）、吲哚青绿血管造影（ICGA）、光学相干断层扫描（OCT）检查。结果23只眼视力均有不同程度提高，1月后视物变形改善有21只眼，6月后视物变形均有好转。最佳矫正视力0．1-0．9，平均0．6。视力明显改善者19只眼，占83％；视力稳定者4只眼，占17％；无视力下降者。OCT检查结果显示，显效18只眼，占78％；有效5只眼，占22％；无神经上皮下积液未吸收或增加者。FFA及ICGA检查结果显示，显效21只眼，占91％；有效2只眼，占9％；无渗漏未改善或加重者。结论1／3剂量维替泊芬PDT治疗慢性CSC具有较好的疗效，但该治疗方法的长期安全性和有效性有待于进一步对照研究来证实。
Objective To explore the effect of photodynamic therapy with one third standard dose verteporfin for chronic central serous chorioretinopathy （CSC）. Methods Twenty-three patients （23 eyes） diagnosed as chronic CSC by the examination of fundus, optical coherence tomography （OCT）, fundus fluoresceine angiography （FFA） and indocyanine green angiography （ICGA）, underwent photodynamic therapy （PDT） with one third standard dose verteporfin by means of specific laser slit lamp. Verteporfin was infused over 8 minutes followed by ICGA guiding laser application for 30 sec- onds. Postoperatively, all patients were followed up for 6-10 months, averaged 7.3 months. During the time of follow-up, examinations included visual acuity measurement, fundus examination, FFA and ICGA. Results The best corrected visual acuity （BCVA） was 0.1-0.9, meanly 0.6. The BCVA increased curiously in 19 eyes （83%）, stabilized in 4 eyes （17 %）, decreased in no one eye. In OCT, the leakage regressed totally in 18 eyes （78%）, mostly in 5 eyes （22%）, while progressed in no one. In FFA, the leakage regressed totally in 21 eyes （91%）, mostly in two eyes （9%）, while pro- gressed in no one. Conclusions PDT with one third standard dose verteporfin is beneficial tochronic CSC, but further controlled study is warranted to demonstrate the safety and efficacy of long time in the therapy.
出处
《中国实用眼科杂志》
2016年第4期354-357,共4页
Chinese Journal of Practical Ophthalmology
